IMforte regimen: The first and only FDA-approved combination for maintenance treatment in 1L ES-SCLC – Nov 4th
For maintenance treatment in 1L extensive-stage small cell lung cancer
On behalf of Genentech, you are invited to attend an expert-led educational presentation: IMforte regimen: The first and only FDA-approved combination for maintenance treatment in 1L ES-SCLC
A review of the trial data for the IMforte regimen (TECENTRIQ + lurbinectedin)
Indication: TECENTRIQ, in combination with lurbinectedin, is indicated for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after firs t-line induction therapy with TECENTRIQ or atezolizumab and hyaluronidas e-tqjs, carboplatin and etopos ide.
Featured Faculty: Kathleen C. Kerrigan, DO. Associate Professor of Medical Oncology Kathryn F. Kirk Center at Hunts man Cancer Institute Salt Lake City, UT
When: Tuesday, November 4, 2025. Arrival Time: 6:30 pm PT. Start Time: 7:00 pm PT
Venue: Town, 716 Laurel Street, San Carlos , CA 94070
Please RSVP: by 10/30/25 to Lisa Reinmann at (415) 297-8278
Program Overview:
• An overview of the SCLC landscape
• An introduction to the IMforte clinical trial design, patient characteristics, and pivotal efficacy and safety data